Nidan Laboratories & Healthcare Ltd

Nidan Laborator's historical performance shows fluctuations, with net sales increasing slightly to 24.53 Cr in March 2025, while profit before tax rebounded to 2.76 Cr from a loss the previous year. Despite a profit recovery, cash flow from operating activities decreased to 2.00 Cr, indicating ongoing challenges.

As of November 10, 2025, Nidan Laborator. is considered undervalued with an attractive valuation grade, highlighted by a PE ratio of 14.25 and an EV to EBITDA of 7.38, making it a compelling investment opportunity despite recent underperformance compared to the Sensex.

As of November 7, 2025, Nidan Laborator is fairly valued with a PE ratio of 14.67 and an EV to EBITDA of 7.55, indicating it is neither undervalued nor significantly overvalued compared to peers, despite struggling with low return metrics and underperforming against the Sensex.

As of November 7, 2025, Nidan Laborator. is fairly valued with a PE ratio of 14.67 and an EV to EBITDA of 7.55, making it more attractive compared to peers like Apollo Hospitals and Narayana Hrudaya, despite a poor year-to-date return of -27.56%.

As of November 7, 2025, Nidan Laborator. is fairly valued with a PE ratio of 14.67, an EV to EBITDA of 7.55, and a Price to Book Value of 0.43, but has underperformed with a year-to-date decline of 27.56% compared to a 7.81% increase in the Sensex.

As of 04-Nov, Nidan Laboratories & Healthcare Ltd is currently priced at 19.85, reflecting a 3.66% increase, but has a troubling long-term performance with a -33.72% return over the past year and significant financial weaknesses. Despite short-term outperformance against the Sensex, ongoing risks remain due to poor fundamentals and a concerning ability to service debt.

As of 24-Sep, Nidan Laboratories & Healthcare Ltd's stock price is declining at 18.70, down 1.84%, with significant underperformance against its sector and the Sensex. The company faces weak fundamentals, highlighted by low profitability metrics and a lack of recent financial results, contributing to ongoing investor concerns.

As of September 23, 2025, Nidan Laborator. is considered attractive due to its undervalued status reflected in a PE ratio of 13.55 and significant discounts compared to peers like Max Healthcare and Apollo Hospitals, despite its recent underperformance against the Sensex.

As of 23-Sep, Nidan Laboratories & Healthcare Ltd's stock price is at 19.05, showing a slight increase today but a significant decline of 43.05% over the past year. Despite recent short-term gains, the company's weak fundamentals and long-term underperformance against the benchmark indicate a challenging outlook.

As of September 22, 2025, Nidan Laborator. is considered very attractive due to its undervalued status with a PE ratio of 13.48, EV to EBITDA of 7.08, and Price to Book Value of 0.39, significantly lower than peers like Max Healthcare and Apollo Hospitals, despite a year-to-date return of -34.14% compared to a 6.59% gain in the Sensex.

As of 22-Sep, Nidan Laboratories & Healthcare Ltd's stock price is at 19.00, reflecting a 0.52% decline. Despite a recent short-term gain, the stock has significantly underperformed over the long term, with a year-to-date drop of 34.14% and concerns over its financial health.

Nidan Laborator's historical performance shows fluctuating financial metrics, with slight growth in net sales and total operating income in Mar'25, but decreased operating profit and cash flow. While profitability improved with a profit after tax of 1.98 Cr in Mar'25, the company faces challenges in consistent revenue growth and managing operational costs.

As of 19-Sep, Nidan Laboratories & Healthcare Ltd's stock price is declining at 19.10, down 1.55%, with a significant annual loss of -43.49% and concerning fundamentals, including a poor EBIT to Interest ratio of 1.75. Despite a slight weekly gain of 2.96%, the stock has consistently underperformed against the benchmark over three years, indicating waning investor confidence.